BAL PHARMA LTD.
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹93.75
- Today's High:
- ₹100
- Open Price:
- ₹100
- 52W Low:
- ₹63.4
- 52W High:
- ₹106.2
- Prev. Close:
- ₹98.01
- Volume:
- 5836
Company Statistics
- Market Cap.:
- ₹1.43 billion
- Book Value:
- 41.051
- Revenue TTM:
- ₹3.05 billion
- Operating Margin TTM:
- 5.61%
- Gross Profit TTM:
- ₹1.09 billion
- Profit Margin:
- 0.78%
- Return on Assets TTM:
- 3.48%
- Return on Equity TTM:
- 4.29%
Company Profile
BAL PHARMA LTD. had its IPO on under the ticker symbol BALPHARMA.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. BAL PHARMA LTD. has a staff strength of 0 employees.
Stock update
Shares of BAL PHARMA LTD. opened at ₹100 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹93.75 - ₹100, and closed at ₹94.48.
This is a -3.6% slip from the previous day's closing price.
A total volume of 5,836 shares were traded at the close of the day’s session.
In the last one week, shares of BAL PHARMA LTD. have slipped by -1.61%.
BAL PHARMA LTD.'s Key Ratios
BAL PHARMA LTD. has a market cap of ₹1.43 billion, indicating a price to book ratio of 2.2841 and a price to sales ratio of 0.4774.
In the last 12-months BAL PHARMA LTD.’s revenue was ₹3.05 billion with a gross profit of ₹1.09 billion and an EBITDA of ₹267.44 million. The EBITDA ratio measures BAL PHARMA LTD.'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, BAL PHARMA LTD.’s operating margin was 5.61% while its return on assets stood at 3.48% with a return of equity of 4.29%.
In Q1, BAL PHARMA LTD.’s quarterly earnings growth was a negative -68.4% while revenue growth was a positive 0.8%.
BAL PHARMA LTD.’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 54.491
- PEG
Its diluted EPS in the last 12-months stands at ₹1.67 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into BAL PHARMA LTD.’s profitability.
BAL PHARMA LTD. stock is trading at a EV to sales ratio of 0.8918 and a EV to EBITDA ratio of 11.026. Its price to sales ratio in the trailing 12-months stood at 0.4774.
BAL PHARMA LTD. stock pays annual dividends of ₹0 per share, indicating a yield of 1.05% and a payout ratio of 1.94%.
Balance sheet and cash flow metrics
- Total Assets
- ₹3.13 billion
- Total Liabilities
- ₹2.09 billion
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 1.94%
BAL PHARMA LTD. ended 2024 with ₹3.13 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹3.13 billion while shareholder equity stood at ₹637.89 million.
BAL PHARMA LTD. ended 2024 with ₹0 in deferred long-term liabilities, ₹2.09 billion in other current liabilities, in common stock, ₹0 in retained earnings and ₹38.29 million in goodwill. Its cash balance stood at ₹14.87 million and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹305.23 million.
BAL PHARMA LTD.’s total current assets stands at ₹2.28 billion while long-term investments were ₹0 and short-term investments were ₹75.94 million. Its net receivables were ₹939.76 million compared to accounts payable of ₹789.23 million and inventory worth ₹980.05 million.
In 2024, BAL PHARMA LTD.'s operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, BAL PHARMA LTD. paid ₹0.02 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹94.48
- 52-Week High
- ₹106.2
- 52-Week Low
- ₹63.4
- Analyst Target Price
- ₹
BAL PHARMA LTD. stock is currently trading at ₹94.48 per share. It touched a 52-week high of ₹106.2 and a 52-week low of ₹106.2. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹95.43 and 200-day moving average was ₹85.89 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 6694.6% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About BAL PHARMA LTD.
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Bal Pharma Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk actives. It provides anti-infectives, pain management, respiratory care, and women’s health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostrate enlargement, renal calculi, male infertility, women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; and cardiac care products under the Secremet and Servace brands. In addition, the company offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, acne treatment, etc.; and various formulations. Further, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India.